4 results about "H influenzae type b" patented technology

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is comprised between 1.5:1 and 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and / or Influenza B.

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNA) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, and methods of eliciting an immune response by administering the same, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) to the mRNA encoding the influenza B virus. In particular, the disclosure relates to mRNA encoding these antigens formulated into lipid nanoparticles (LNPs).

Provided herein are monoclonal antibodies or antigen-binding fragments thereof that bind to an influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies, and methods of use. The antibodies can be used to inhibit or neutralize the activity of an influenza B virus, thereby providing a method of treating or preventing an influenza infection in a human. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral adsorption and / or entry into a host cell. The antibodies can be used prophylactically or therapeutically, and can be used alone or in combination with one or more other antiviral agents or vaccines.